As of May 2026, FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List, with a public comment period closing June 29, 2026
These include: Pancreatitis (Inflammation of the Pancreas) Gallbladder Disease & Gallstones Kidney Function Changes Metabolic Effects (e.g., Low Blood Sugar) Rare & Emerging Safety Signals Although rare, ongoing safety monitoring continues to identify possible associations and warrant caution: Rare events underscore why medical supervision and regular monitoring are crucial during treatment
Briefly, the primer pairs used were F: 5'-TGAAGGAGAAGGTGTCTGCGGGA-3' and R: 5'-AGGACGGTGCGGTGAGAGTG-3'
While Zepbound is already a commercial success, retatrutides emerging clinical profile suggests it may raise the efficacy bar even further, though with potential trade-offs
This triple-agonist design incorporates GIP receptor activation alongside the GLP-1 and glucagon pathways
Levocarnitine may add mild GI effects, increased injection site irritation, and rarely a fishy body odor at higher doses